Nurix Therapeutics is trading 7.86% down at $22.50 before the October 19, 2026 open, alongside biotech-sector weakness; no company-specific catalyst was identified. - XBI is down 3.65% in the supplied pre-market data. Sector pressure may be contributing, but no explicit report linked it to Nurix’s move. - The latest substantive company update was its October 12 quarterly report and corporate update.